On November 4, 2025 BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, reported that an abstract submitted in collaboration with Eleison Pharmaceuticals has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI), to be held January 8–10, 2026, in San Francisco, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma," will be featured in Poster Session B on January 9. It will also be published in the ASCO (Free ASCO Whitepaper) GI 2026 online proceedings and subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium.
Co-authored by Richard Kim, MD, Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, Nikolas Naleid, MD, PharmD, Hematology/Oncology Fellow at Moffitt Cancer Center, Eleison Pharmaceuticals and BullFrog AI, the study explores data-driven precision-oncology approaches to identify patient subtypes that may demonstrate enhanced response to glufosfamide, an investigational chemotherapeutic agent for pancreatic cancer. The research leverages BullFrog AI’s bfLEAP and bfPREP platforms to analyze complex clinical datasets and uncover biologically meaningful patient clusters.
"This acceptance by ASCO (Free ASCO Whitepaper) underscores the growing recognition of AI’s ability to transform oncology research," said Vin Singh, CEO of BullFrog AI. "Our collaboration with Eleison Pharmaceuticals clearly demonstrates how causal AI can help reveal critical insights that guide more precise, effective treatment strategies for difficult cancers like pancreatic adenocarcinoma."
Results from the study will be presented during the poster session, and in accordance with ASCO (Free ASCO Whitepaper)’s embargo policy, no additional data will be publicly disclosed until the official embargo lifts prior to the presentation.
(Press release, Bullfrog AI, NOV 4, 2025, View Source [SID1234659346])